We are delighted to deliver you our latest IP Spotlight publication.
In this edition, we provide an update on the new transparency measures for prescription medicines, as released by Australia’s Therapeutic Goods Administration. We report on implications of recent changes to the Patent Law and Guidelines for Examination in China, which have established that post-filing data for demonstrating the patentability of the claimed inventions shall not be prohibited. We also use this edition of IP Spotlight to discuss the continuous and fast-paced evolution of design protection.
If any of our articles raise questions or concerns regarding your IP or practice, please reach out to Wrays’ experts for clarification.
For now, enjoy the read!
